Mereo Biopharma 5, Inc.
Records under this name other than the patents Mereo Biopharma 5, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 46 patents it holds.
Back to Mereo Biopharma 5, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,136,384 | Methods for Treatment of Cancer Comprising Tigit-Binding Agents now held by Mereo Biohparma 5, Inc. In force · High confidence | In force | High confidence | |
| US 11,230,596 | Methods for Treatment of Cancer Comprising Tigit-Binding Agents now held by Mereo Biohparma 5, Inc. In force · High confidence | In force | High confidence | |
| US 8,324,361 | Nucleic Acid Molecules Encoding Soluble Frizzled (FZD) Receptors Term ended Term ended Oct 31, 2026 · High confidence | Term ended | Term ended Oct 31, 2026 | High confidence |
| US 9,228,013 | Methods of Using the Fri Domain of Human Frizzled Receptor for Inhibiting WNT Signaling in a Tumor or Tumor Cell Term ended Term ended Oct 31, 2026 · High confidence | Term ended | Term ended Oct 31, 2026 | High confidence |
| US 9,732,139 | Methods of Treating Cancer by Administering a Soluble Receptor Comprising a Human FC Domain and the Fri Domain from Human Frizzled Receptor Term ended Term ended Oct 31, 2026 · High confidence | Term ended | Term ended Oct 31, 2026 | High confidence |
| US 9,850,311 | Compositions and methods for diagnosing and treating cancer Term ended Term ended Oct 31, 2026 · High confidence | Term ended | Term ended Oct 31, 2026 | High confidence |
| US 8,784,811 | Method of Treating Cancer Using Antibodies to a Non-Ligand Binding Region of NOTCH1 Lapsed on the fee record Ended Jul 22, 2026 · High confidence | Lapsed on the fee record | Ended Jul 22, 2026 | High confidence |
| US 8,765,913 | Human Frizzled (FZD) Receptor Polypeptides and Methods of Use Thereof for Treating Cancer and Inhibiting Growth of Tumor Cells Lapsed on the fee record Ended Jul 1, 2026 · High confidence | Lapsed on the fee record | Ended Jul 1, 2026 | High confidence |
| US 9,982,042 | Therapeutic Combination and Methods of Treatment With A DLL4 Antagonist and an Anti-Hypertensive Agent Lapsed on the fee record Ended May 29, 2026 · High confidence | Lapsed on the fee record | Ended May 29, 2026 | High confidence |
| US 8,551,479 | Methods for Treating Melanoma Lapsed on the fee record Ended Oct 8, 2025 · High confidence | Lapsed on the fee record | Ended Oct 8, 2025 | High confidence |